EvolveImmune Therapeutics Funding: $35M Raised, Series A
EvolveImmune Therapeutics has raised $35M in total funding. Latest round: Series A. Backed by Pfizer, Solasta Ventures, Takeda.
EvolveImmune Therapeutics funding overview
EvolveImmune Therapeutics has raised $35M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in January 2024. The round record for EvolveImmune Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include Pfizer, Solasta Ventures, Takeda, Elm Street Ventures, Yonjin Venture. 5 distinct backers are named across the disclosed rounds.
EvolveImmune Therapeutics at a glance
Total raised
$35M
Latest round
Series A
Latest round date
January 2024
Notable investors
Pfizer, Solasta Ventures, Takeda, Elm Street Ventures, Yonjin Venture
Frequently asked about EvolveImmune Therapeutics funding
How much has EvolveImmune Therapeutics raised?
EvolveImmune Therapeutics has raised $35M in total disclosed funding across the rounds on record.
Who has invested in EvolveImmune Therapeutics?
Pfizer, Solasta Ventures, Takeda, Elm Street Ventures, Yonjin Venture are named among the investors backing EvolveImmune Therapeutics.
What was the latest EvolveImmune Therapeutics funding round?
The most recent disclosed round is a Series A, announced in January 2024.
Where is EvolveImmune Therapeutics based?
No headquarters location is disclosed for EvolveImmune Therapeutics.
When did EvolveImmune Therapeutics last raise?
The last disclosed EvolveImmune Therapeutics round closed in January 2024 at Series A.
Totals shown for EvolveImmune Therapeutics aggregate every disclosed round on file. To see how that compares, browse the companies and the investors behind them below.
Companies related to EvolveImmune Therapeutics (12)
